Bevacizumab in breast cancer: the best is yet to come?
作者信息
Puhalla Shannon, Brufsky Adam
机构信息
Comprehensive Breast Program, University of Pittsburgh, Cancer Institute, Division of Hematology-Oncology, Magee Women's Hospital, Pittsburgh, Pennsylvania, USA.
出版信息
Oncology (Williston Park). 2009 Apr 15;23(4):332, 335.
PMID:19476262
Abstract
摘要
相似文献
1
Bevacizumab in breast cancer: the best is yet to come?贝伐单抗治疗乳腺癌：最佳效果尚未到来？
Oncology (Williston Park). 2009 Apr 15;23(4):332, 335.
2
Optimizing outcomes with bevacizumab by better targeting patients and tumors.通过更精准地靶向患者和肿瘤来优化贝伐单抗的治疗效果。
Oncology (Williston Park). 2009 Apr 15;23(4):339-40.
3
Bevacizumab in the treatment of metastatic breast cancer.贝伐单抗治疗转移性乳腺癌。
Oncology (Williston Park). 2009 Apr 15;23(4):327-32.
4
Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.贝伐珠单抗用于人表皮生长因子受体 2 阴性的晚期乳腺癌的一线治疗。
Curr Opin Oncol. 2011 Apr;23 Suppl:S3-9. doi: 10.1097/01.cco.0000397417.75245.9c.
5
Success of bevacizumab trials raises questions for future studies.贝伐单抗试验的成功给未来的研究提出了问题。
J Natl Cancer Inst. 2005 Jul 6;97(13):950-1. doi: 10.1093/jnci/dji194.
6
Avastin withdrawal symptoms.阿瓦斯汀撤药症状。
Expert Opin Pharmacother. 2012 Feb;13(3):293-8. doi: 10.1517/14656566.2012.652088. Epub 2012 Jan 21.
7
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?贝伐单抗引起的心血管事件：胆固醇栓塞综合征的后果？
J Natl Cancer Inst. 2007 Jan 3;99(1):85-6. doi: 10.1093/jnci/djk011.
8
Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.转移性乳腺癌的抗血管生成疗法——一个未实现的梦想。
Lancet Oncol. 2011 Apr;12(4):316-8. doi: 10.1016/S1470-2045(11)70060-2. Epub 2011 Mar 21.
9
Bevacizumab and breast cancer: the E2100 outlier.贝伐单抗与乳腺癌：E2100研究中的异常情况。
Lancet Oncol. 2010 Dec;11(12):1117-9. doi: 10.1016/S1470-2045(10)70259-X.
10
Bevacizumab for advanced breast cancer: all tied up with a RIBBON?贝伐单抗用于晚期乳腺癌：与RIBBON试验密切相关？
J Clin Oncol. 2011 Apr 1;29(10):1232-5. doi: 10.1200/JCO.2010.33.2684. Epub 2011 Mar 7.
Zotero 插件